GENPF (Genix Pharmaceuticals) Short-Term Debt: $0.84 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genix Pharmaceuticals Short-Term Debt?

Genix Pharmaceuticals GENPF Short-Term Debt is $0.84 Mil as of Apr. 2026. The stock has 3 warning signs investors should review.

Genix Pharmaceuticals's Short-Term Debt for the quarter that ended in Apr. 2026 was $0.84 Mil.

Genix Pharmaceuticals's quarterly Short-Term Debt increased from Oct. 2025 ($0.75 Mil) to Jan. 2026 ($0.78 Mil) and increased from Jan. 2026 ($0.78 Mil) to Apr. 2026 ($0.84 Mil).

Genix Pharmaceuticals's annual Short-Term Debt increased from Oct. 2023 ($0.37 Mil) to Oct. 2024 ($0.59 Mil) and increased from Oct. 2024 ($0.59 Mil) to Oct. 2025 ($0.75 Mil).

Genix Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genix Pharmaceuticals Short-Term Debt Related Terms

Genix Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals Short-Term Debt Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.13 0.37 0.59 0.75

Genix Pharmaceuticals Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.75 0.75 0.78 0.84
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.84 Mil mean?
Genix Pharmaceuticals (GENPF) has a Short-Term Debt of $0.84 Mil as of Apr. 2026.
Is Genix Pharmaceuticals' Short-Term Debt too high?
Genix Pharmaceuticals' current Short-Term Debt is $0.84 Mil.
How does Genix Pharmaceuticals' Short-Term Debt compare to ZTS and UTHR?
Genix Pharmaceuticals' Short-Term Debt of $0.84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Genix Pharmaceuticals's current Short-Term Debt is $0.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current Short-Term Debt of $0.84 Mil. The current Short-Term Debt is $0.84 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current Short-Term Debt is $0.84 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.